Experienced in Pure Red Cell Aplasia

Dr. Craig Reeder

Hematology | Oncology
Mayo Clinic Hospital In Arizona
5777 E Mayo Blvd, 
Phoenix, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Pure Red Cell Aplasia
Mayo Clinic Hospital In Arizona
5777 E Mayo Blvd, 
Phoenix, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Craig Reeder is a Hematologist and an Oncologist in Phoenix, Arizona. Dr. Reeder is rated as an Experienced provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Waldenstrom Macroglobulinemia, Multiple Myeloma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 85 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in MN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Mayo Clinic Hospital In Arizona
5777 E Mayo Blvd, Phoenix, AZ 85054

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase2 Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed/ Refractory Lymphoma, Patients With Clonal Cytopenia of Undetermined Significance, and Chronic Myelomonocytic Leukemia
Phase2 Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed/ Refractory Lymphoma, Patients With Clonal Cytopenia of Undetermined Significance, and Chronic Myelomonocytic Leukemia
Enrollment Status: Recruiting
Publish Date: February 09, 2026
Intervention Type: Procedure, Drug, Biological, Other, Dietary supplement
Study Drugs: Carboplatin, Cisplatin, Cytarabine, Dexamethasone, Etoposide, Gemcitabine Hydrochloride, Ifosfamide, Oxaliplatin, Rituximab
Study Phase: Phase 2
Effect of Vitamin D Replacement on Tumor Response and Survival Parameters for Vitamin D Insufficient Patients With Cancer
Effect of Vitamin D Replacement on Tumor Response and Survival Parameters for Vitamin D Insufficient Patients With Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Dietary supplement, Other
Study Drug: Cholecalciferol
Study Phase: Not Applicable
Phase 2 Trial of Ixazomib Combinations in Patients With Relapsed Multiple Myeloma
Phase 2 Trial of Ixazomib Combinations in Patients With Relapsed Multiple Myeloma
Enrollment Status: Completed
Publish Date: September 05, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dexamethasone, Ixazomib Citrate
Study Phase: Phase 2
Phase I/II Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R2CHOP) Chemoimmunotherapy in Patients With Newly Diagnosed Diffuse Large Cell and Follicular Grade IIIA/B B Cell Lymphoma
Phase I/II Study of Lenalidomide (Revlimid), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R2CHOP) Chemoimmunotherapy in Patients With Newly Diagnosed Diffuse Large Cell and Follicular Grade IIIA/B B Cell Lymphoma
Enrollment Status: Completed
Publish Date: January 10, 2025
Intervention Type: Drug, Biological, Other, Genetic
Study Drugs: Pegfilgrastim, Rituximab, Cyclophosphamide, Doxorubicin, Lenalidomide, Prednisone, Vincristine
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: BGB-3111 (Zanubrutinib), Ibrutinib
Study Phase: Phase 3
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Completed
Publish Date: April 18, 2024
Intervention Type: Biological, Drug
Study Drug: CTL019
Study Phase: Phase 2
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
Phase I Trial of Pomalidomide for Patients With Relapsed/Refractory Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma
Phase I Trial of Pomalidomide for Patients With Relapsed/Refractory Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma
Enrollment Status: Completed
Publish Date: July 22, 2019
Intervention Type: Drug, Other
Study Phase: Phase 1
View 7 Less Clinical Trials

85 Total Publications

Multi-omics analysis reveals a unique epigenetic signature in MYD88 wild-type Waldenstrom macroglobulinemia.
Multi-omics analysis reveals a unique epigenetic signature in MYD88 wild-type Waldenstrom macroglobulinemia.
Journal: Haematologica
Published: August 28, 2025
Similar Doctors
Advanced in Pure Red Cell Aplasia
Dr. Misam Zawit
Oncology
Advanced in Pure Red Cell Aplasia
Dr. Misam Zawit
Oncology

City Of Hope Phoenix Cancer Center

14200 W Celebrate Life Way, 
Goodyear, AZ 
 (27.4 miles away)
866-414-0546
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Misam Zawit is an Oncologist in Goodyear, Arizona. Dr. Zawit is rated as an Advanced provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria (PNH), Fanconi Anemia, Endoscopy, and Colonoscopy.

Experienced in Pure Red Cell Aplasia
Dr. Sanjay Shah
Hematology | Oncology
Experienced in Pure Red Cell Aplasia
Dr. Sanjay Shah
Hematology | Oncology

Phoenix Children's

1919 E Thomas Rd, 
Phoenix, AZ 
 (13.3 miles away)
602-933-0920
Languages Spoken:
English
See accepted insurances

Sanjay Shah is a Hematologist and an Oncologist in Phoenix, Arizona. Dr. Shah is rated as an Advanced provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Beta Thalassemia, and Congenital Hemolytic Anemia.

Experienced in Pure Red Cell Aplasia
Dr. Cecilia Arana
Hematology | Oncology
Experienced in Pure Red Cell Aplasia
Dr. Cecilia Arana
Hematology | Oncology

AZ - Cancer

5777 E Mayo Blvd, 
Phoenix, AZ 
 (0.1 miles away)
480-933-6836
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Cecilia Arana is a Hematologist and an Oncologist in Phoenix, Arizona. Dr. Arana is rated as a Distinguished provider by MediFind in the treatment of Pure Red Cell Aplasia. Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Reeder's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 25 Advanced Conditions
View All 79 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile